They specifically target BRAF cancer carrying a mutation at V600E (designated V600E BRAF) that occurs in about 50%–60% of melanomas and about 6%–8% of all solid tumors, including colorectal, thyroid, and ovarian tumors [42]. This evidence concerns the gene BRAF and cancer.